From the Desk of the Editor: Volume 5, Issue 4

Dear Colleagues, As the 2020 pandemic has altered our behavioral, economic, educational policies, and numerous other career and life events worldwide, SARS-CoV-2 has also impacted global healthcare and patient outcomes. Fortunately, and not unexpectedly, frontline and advanced line healthcare workers, researchers, and scientists have never ceased the tradition of tireless sacrifice and dedication to advancing patient care. Assuredly we have reviewed and read exceptional cancer care advancements in 2020, including innovative efforts for delivering care via ambulatory processes or through virtual technologies while prioritizing our most vulnerable patient populations. Fortunately, numerous diagnostic and therapeutic advancements in 2020 have occurred in Genitourinary Oncology.

While safeguarding both patients and the healthcare team from unnecessary risk of SARS-CoV-2, telehealth technology and its widespread adoption among healthcare practitioners and patients have allowed for innovative patient care strategies. Virtual education has also persevered and improved during this year of in-person and travel adversity.

READ MORE PREVIOUS ARTICLES

Neal Shore, MD, FACS

Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 350 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Bladder Cancer Advocacy Network, and is Immediate Past President, Large Urology Group Practice Association. He is a founder for both: CUSP Clinical Trials Consortium, as well as for DASHKO, large urology practices data registries. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee and the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE (Academic Editor), Urology Practice, World Journal of Urology, and serves as Editor, Everyday Urology-Oncology. He has more than 200 peer-reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, New England Journal of Medicine, European Urology, Journal Urology, Urology, BJUI, PCPD, and numerous other high impact scientific journals. A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6-month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.


Everyday Urology: Volume 5, Issue 4

In this issue

Download PDF

Everyday Urology: Volume 5, Issue 3

In this issue

Download PDF

Everyday Urology: Volume 5, Issue 2

In this issue

Download PDF

Everyday Urology: Volume 5, Issue 1

In this issue

Download PDF

DISCLAIMER: The statements and opinions contained in the articles of Everyday Urology®-Oncology Insights are solely those of the authors and contributors. The appearance of the advertisements in the publication is not a warranty, endorsement or approval of the products or services advertised or their effectiveness, quality or safety. The content of the publication may contain discussion of off-label uses of some of the agents mentioned. Please consult the prescribing informationfor full disclosure of approved uses. To the extent permissible under applicable laws, no responsibility is assumed by the publisher for any injury and/or damage as a result of any actual or alleged libelous statements, infringement of intellectual property, or privacy rights, or products liability whether resulting from negligence or otherwise, or for any use of operation, ideas, instructions, procedures, products, or methods contained within the material.

Everyday Urology®-Oncology Insights (ISSN 2473-3784) is published four times a year by Digital Science Press, Inc., business office located at 548 Market St #41552, San Francisco, CA 94104-5401

POSTMASTER: Send address changes to Everyday Urology®-Oncology Insights Digital Science Press, Inc. Subscription Customer Service, 548 Market St #41552, San Francisco, CA 94104-5401

Customer service: Customer service inquiries should be sent to Subscription inquiries should be sent to: Access to this journal is online at www.urotoday.com Other correspondence for Digital Science Press, Inc. should be sent to: Attention: Digital Science Press, Inc. 548 Market St #41552, San Francisco, CA 94104-5401

COPYRIGHT AND PERMISSIONS: Everyday Urology®-Oncology Insights is published four times a year by Digital Science Press. No portion of the work(s) can be reproduced without written consent from the Publisher. Permission may be requested directly from the Publisher Email: ©Copyright 2019.